10% Upside If J&J Is Even Partially Successful In Its R&D Plan

Positive data for pipeline drugs could lead to our forecasts being conservative. For instance, it remains to be seen how Zytiga?s label extension will help it compete against Xtandi. There are additional clinical data that could potentially strengthen Imbruvica?s sales, going forward. Also, the company is likely to file multiple immunology and oncology drugs for FDA review in the next two to three years. More than expected success could add additional $5-$6 billion in annual revenues by 2021. Th...